

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number

Filing Date

On Even Date Herewith

First Named Inventor

Irvin COHEN

Group Art Unit

1642

Examiner Name

Attorney Docket Number

COHEN=42A

U.S. PATENT DOCUMENTS

[illegible]

U.S. PTO

~~2022/07~~

01/02/02

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 3

Complete if Known

Application Number	
Filing Date	On Even Date Herewith
First Named Inventor	Irun COHEN
Group Art Unit	1642
Examiner Name	
Attorney Docket Number	COHEN=42A

Jt821 U.S. PTO
10/032482**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AG	COHEN, "Natural Id-Anti-Id Networks and the Immunological Homunculus", in <u>Theories of Immune Networks</u> (Atlan et al, ed.), Springer-Verlag; Heidelberg (1989) pp. 6-12	
	AH	COHEN, "The cognitive paradigm and the immunological homunculus", <u>Immunol Today</u> 13(12):490-494 (1992)	
	AI	EL-DEIRY et al, "Definition of a consensus binding site for p53", <u>Nature Genet</u> 1(4):45-49 (1992)	
	AJ	FOORD et al, "A DNA binding domain is contained in the C-terminus of wild type p53 protein", <u>Nucleic Acids Res</u> 19(19):5191-5198 (1991)	
	AK	GANNON et al, "Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form", <u>EMBO J</u> 9(5):1595-1602 (1990)	
	AL	HARLOW et al, "Monoclonal antibodies specific for simian virus 40 tumor antigens", <u>J Virol</u> 39:861-869 (1981)	
	AM	HOLLSTEIN et al, "p53 mutations in human cancers", <u>Science</u> 253:49-53 (1991)	
	AN	HOUBIERS et al, "In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53", <u>Eur J Immunol</u> 23:2072-2077 (1993)	
	AO	JANNOT et al, "Characterization of scFv-421, a Single-Chain Antibody Targeted to p53", <u>Biochem Biophys Res Comm</u> 230:242-246 (1997)	
	AP	LEE et al, "p53 and its 14Kda C-terminal domain recognize primary DNA damage in the form of insertion/deletion", <u>Cell</u> , 81:1013-1020 (1995)	
	AQ	LUBIN et al, "Analysis of p53 30 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface", <u>Cancer Res</u> 53:5872-5876 (1993)	
	AR	NICHOLSON et al, "Anti-tumor immune responses following monoclonal antibody therapy of ovarian cancer", <u>Proc Ann Meet Am Asso Cancer Res</u> , Vol. 38, (XP002081861) (1997)	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	
		Filing Date	On Even Date Herewith
		First Named Inventor	Irun COHEN
		Group Art Unit	1642
		Examiner Name	
		Attorney Docket Number	COHEN=42A
Sheet	3	of	3

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AS	NISONOFF et al, "Idiotypes: concepts and applications", <u>J Immunol</u> 147:2429-2438 (1991)	
	AT	PAUL, <u>Fundamental Immunology</u> , Raven Press, NY, Chapter 8, p. 242 (1993)	
	AU	RUIZ et al, "Idiotypic immunization induces immunity to mutated p53 and tumor rejection", <u>Nature Med</u> 4(6):710-712 (1998)	
	AV	SCHLICHTHOLZ et al, "The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot", <u>Cancer Res</u> 52:6380-6384 (1992)	
	AW	SOUSSE T, "The humoral response to the tumor suppressor gene product p53 in human cancer. Implications for diagnosis and therapy", <u>Immunol Today</u> 17:354-356 (1996)	
	AX	STEVENSON et al, "Idiotypic DNA vaccines against B-cell lymphoma", <u>Immunol Rev</u> 145:211-228 (1995)	
	AY	TILKIN et al, "Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer", <u>Eur J Immunol</u> 25:1765-1769 (1995)	
	AZ	WOLKOWICZ et al, "The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes", <u>Oncogene</u> 10:1167-1174 (1995)	
	BA	YANUCK et al, "A mutant p53 tumor suppressor protein is a target for peptide-induced CD8 ⁺ cytotoxic T-cells", <u>Cancer Res</u> 53:3257-3261 (1993)	
	BB	ZUSMAN et al, "Tumor-Suppressor effects of anti-p53 IgG on chemical induced colon cancer in rats", <u>Cancer J</u> 10(2):116-120 (1997)	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.